Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lincomycin + triamcinolone is a combination drug consisting of the lincosamide antibiotic lincomycin and the synthetic corticosteroid triamcinolone. This combination is primarily used as an intralesional injection for dermatological conditions characterized by inflammation and/or infection, such as nodulocystic acne and hidradenitis suppurativa. Lincomycin acts by inhibiting bacterial protein synthesis, targeting susceptible Gram-positive bacteria including *Staphylococcus* and *Streptococcus* species[8][10]. Triamcinolone exerts anti-inflammatory effects by suppressing multiple inflammatory cytokines through glucocorticoid receptor agonism[5]. The combination leverages both antibacterial (lincomycin) and anti-inflammatory (triamcinolone) actions to reduce lesion size, pain, inflammation, and recurrence in severe or recalcitrant skin diseases. Clinical studies have shown that this combination is more effective than corticosteroid monotherapy for nodulocystic acne[3][7] and improves quality of life in hidradinits suppurativa patients when administered via ultrasound-guided intralesional injection[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lincomycin + triamcinolone.